STRATA excimer laser plus oral JAK inhibitors lifts pediatric vitiligo response to 85.5%

STRATA Skin Sciences, Inc.

STRATA Skin Sciences, Inc.

SSKN

0.00
  • STRATA Skin Sciences highlighted a peer-reviewed randomized trial in the Journal of the American Academy of Dermatology, with results already published online on March 19, 2026.
  • The study found that combining the company’s 308-nm excimer laser with oral JAK inhibitors delivered substantially better repigmentation outcomes in children with progressive vitiligo than an excimer-laser regimen paired with topical tacrolimus.
  • Safety was described as favorable over 48 weeks, with reported side effects characterized as manageable.
  • The publication supports STRATA’s strategy to position its XTRAC excimer laser as a core component in combination regimens, alongside an intellectual property push aimed at protecting laser-based combinations with systemic drugs.
  • Separately, updated AMA CPT codes 96920-96922 are set to expand reimbursement eligibility for excimer laser treatments to additional inflammatory and autoimmune skin conditions effective Jan. 1, 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. STRATA Skin Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605180830PRIMZONEFULLFEED9720204) on May 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.